From molecular glue discovery to the development of degrader-antibody conjugates, pharma is transforming through strategic transactions and by leveraging protein degradation technologies to expand target discovery and drug previously ‘undruggable’ targets.

This provides biotech with the opportunity to understand pharma’s targets of interest and the options for increased specificity and selectivity compared to traditional molecules.

Join the TPD & Induced Proximity Pharma Partnering Summit to accelerate partnership interest in your protein degradation pipeline or platform, by hearing first-hand:

• What: What are pharma’s targets of interest, and what data is sparking or prohibiting deal-making across TPD?
• Who: Who is the right person at each pharma, specifically for induced proximity assets?
• How: How are pharma analyzing data for a research collaboration versus a licensing deal?

VIEW THE FULL EVENT GUIDE

Secure your place here or get in touch with the team – info@hansonwade.com